BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 7803899)

  • 1. Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia.
    Cole-Sinclair MF; Foroni L; Hoffbrand AV
    Baillieres Clin Haematol; 1994 Jun; 7(2):183-233. PubMed ID: 7803899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.
    Drexler HG; Borkhardt A; Janssen JW
    Leuk Lymphoma; 1995 Nov; 19(5-6):359-80. PubMed ID: 8590836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
    Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
    Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
    Li AH; Forestier E; Rosenquist R; Roos G
    Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease in acute lymphoblastic leukaemia--PCR analysis of immunoglobulin gene rearrangements.
    Cole-Sinclair M; Foroni L; Wright F; Mehta A; Prentice HG; Hoffbrand AV
    Leuk Lymphoma; 1993; 11 Suppl 2():49-58. PubMed ID: 8124233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.
    Cazzaniga G; d'Aniello E; Corral L; Biondi A
    Best Pract Res Clin Haematol; 2002 Dec; 15(4):623-38. PubMed ID: 12617867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
    Potter MN; Steward CG; Oakhill A
    Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
    Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection.
    Baruchel A; Cayuela JM; MacIntyre E; Berger R; Sigaux F
    Br J Haematol; 1995 May; 90(1):85-93. PubMed ID: 7786801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
    Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.